Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Receivables (2016 - 2019)

Aptevo Therapeutics (APVO) has disclosed Receivables for 5 consecutive years, with $7.0 million as the latest value for Q4 2019.

  • Quarterly Receivables rose 34.52% to $7.0 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2019, up 34.52% year-over-year, with the annual reading at $7.0 million for FY2019, 34.52% up from the prior year.
  • Receivables hit $7.0 million in Q4 2019 for Aptevo Therapeutics, down from $7.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $8.5 million in Q2 2016 to a low of $100000.0 in Q3 2016.
  • Historically, Receivables has averaged $4.5 million across 5 years, with a median of $5.8 million in 2019.
  • Biggest five-year swings in Receivables: crashed 95.24% in 2016 and later skyrocketed 2998.0% in 2018.
  • Year by year, Receivables stood at $6.5 million in 2015, then plummeted by 95.24% to $307000.0 in 2016, then surged by 597.39% to $2.1 million in 2017, then skyrocketed by 143.81% to $5.2 million in 2018, then soared by 34.52% to $7.0 million in 2019.
  • Business Quant data shows Receivables for APVO at $7.0 million in Q4 2019, $7.9 million in Q3 2019, and $7.4 million in Q2 2019.